HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice.

Abstract
The mammalian (mechanistic) target of rapamycin (mTOR) regulates critical immune processes that remain incompletely defined. Interest in mTOR inhibitor drugs is heightened by recent demonstrations that the mTOR inhibitor rapamycin extends lifespan and healthspan in mice. Rapamycin or related analogues (rapalogues) also mitigate age-related debilities including increasing antigen-specific immunity, improving vaccine responses in elderly humans, and treating cancers and autoimmunity, suggesting important new clinical applications. Nonetheless, immune toxicity concerns for long-term mTOR inhibition, particularly immunosuppression, persist. Although mTOR is pivotal to fundamental, important immune pathways, little is reported on immune effects of mTOR inhibition in lifespan or healthspan extension, or with chronic mTOR inhibitor use. We comprehensively analyzed immune effects of rapamycin as used in lifespan extension studies. Gene expression profiling found many and novel changes in genes affecting differentiation, function, homeostasis, exhaustion, cell death, and inflammation in distinct T- and B-lymphocyte and myeloid cell subpopulations. Immune functions relevant to aging and inflammation, and to cancer and infections, and innate lymphoid cell effects were validated in vitro and in vivo. Rapamycin markedly prolonged lifespan and healthspan in cancer- and infection-prone mice supporting disease mitigation as a mechanism for mTOR suppression-mediated longevity extension. It modestly altered gut metagenomes, and some metagenomic effects were linked to immune outcomes. Our data show novel mTOR inhibitor immune effects meriting further studies in relation to longevity and healthspan extension.
AuthorsVincent Hurez, Vinh Dao, Aijie Liu, Srilakshmi Pandeswara, Jonathan Gelfond, Lishi Sun, Molly Bergman, Carlos J Orihuela, Veronica Galvan, Álvaro Padrón, Justin Drerup, Yang Liu, Paul Hasty, Zelton Dave Sharp, Tyler J Curiel
JournalAging cell (Aging Cell) Vol. 14 Issue 6 Pg. 945-56 (Dec 2015) ISSN: 1474-9726 [Electronic] England
PMID26315673 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright© 2015 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
Chemical References
  • Antibiotics, Antineoplastic
  • Interleukins
  • Pdcd1 protein, mouse
  • Programmed Cell Death 1 Receptor
  • Flagellin
  • mTOR protein, mouse
  • TOR Serine-Threonine Kinases
  • Sirolimus
Topics
  • Aging (drug effects)
  • Animals
  • Antibiotics, Antineoplastic (pharmacology)
  • B-Lymphocytes (immunology)
  • CD8-Positive T-Lymphocytes (immunology)
  • Cell Differentiation (drug effects)
  • Dendritic Cells (immunology)
  • Female
  • Flagellin (immunology)
  • Gastrointestinal Microbiome
  • Gene Expression Profiling
  • Immunologic Memory (immunology)
  • Interleukins (metabolism)
  • Longevity (drug effects, immunology)
  • Male
  • Melanoma, Experimental
  • Mice
  • Mice, Inbred C57BL
  • Myeloid Cells (immunology)
  • Programmed Cell Death 1 Receptor (biosynthesis)
  • Sirolimus (pharmacology)
  • Spleen (cytology, immunology)
  • T-Lymphocytes, Regulatory (cytology, immunology)
  • TOR Serine-Threonine Kinases (antagonists & inhibitors, immunology)
  • Interleukin-22

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: